BUPIVACAINE HYDROCHLORIDE INJECTION, USP SOLUTION

Maa: Kanada

Kieli: englanti

Lähde: Health Canada

Aktiivinen ainesosa:

BUPIVACAINE HYDROCHLORIDE

Saatavilla:

STERIMAX INC

ATC-koodi:

N01BB01

INN (Kansainvälinen yleisnimi):

BUPIVACAINE

Annos:

5MG

Lääkemuoto:

SOLUTION

Koostumus:

BUPIVACAINE HYDROCHLORIDE 5MG

Antoreitti:

BLOCK/INFILTRATION

Kpl paketissa:

100

Prescription tyyppi:

Ethical

Terapeuttinen alue:

LOCAL ANESTHETICS

Tuoteyhteenveto:

Active ingredient group (AIG) number: 0108896004; AHFS:

Valtuutuksen tilan:

APPROVED

Valtuutus päivämäärä:

2020-09-11

Valmisteyhteenveto

_ _
_Bupivacaine Hydrochloride Injection, USP Product Monograph Page 1 of
35_
PRODUCT MONOGRAPH
BUPIVACAINE HYDROCHLORIDE INJECTION, USP
2.5 mg/mL,
5 mg
/mL and 7.5 mg/mL Bupivacaine Hydrochloride, USP
Sterile Solution
Local Anesthetic
STERIMAX INC.
Oakville, Ontario
2770 Portland Drive
L6H 6R4
Date of Preparation:
September 8, 2020
Submission Control No: 238228
_ _
_Bupivacaine Hydrochloride Injection, USP Product Monograph Page 2 of
35_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
.......................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
CONTRAINDICATIONS
..................................................................................................
4
WARNINGS AND PRECAUTIONS
.................................................................................
4
ADVERSE REACTIONS
.................................................................................................
10
DRUG INTERACTIONS
.................................................................................................
13
DOSAGE AND ADMINISTRATION
.............................................................................
14
OVERDOSAGE
...............................................................................................................
18
ACTION AND CLINICAL PHARMACOLOGY
........................................................... 21
STORAGE AND STABILITY
.........................................................................................
23
SPECIAL HANDLING INSTRUCTIONS
......................................................................
24
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................ 24
PART II: SCIENTIFIC INFORMATION
..............................................................................
26
PHARMACEUTICAL INFORMATION
.................................